Hawchar, F., Tomescu, D., Träger, K., Joskowiak, D., Kogelmann, K., Soukup, J., Friesecke, S., Jacob, D., Gummert, J., Faltlhauser, A., Aucella, F., van Tellingen, M., Malbrain, M. L. N. G., Bogdanski, R., Weiss, G., Herbrich, A., Utzolino, S., Nierhaus, A., Baumann, A., ... Brunkhorst, F. M. (2022). Hemoadsorption in the critically ill-Final results of the International CytoSorb Registry. PLoS One, 17(10), e0274315. https://doi.org/10.1371/journal.pone.0274315
Hawchar, F, Tomescu, D, Träger, K, Joskowiak, D, Kogelmann, K, Soukup, J, Friesecke, S, Jacob, D, Gummert, J, Faltlhauser, A, Aucella, F, van Tellingen, M, Malbrain, MLNG, Bogdanski, R, Weiss, G, Herbrich, A, Utzolino, S, Nierhaus, A, Baumann, A, Hartjes, A, Henzler, D, Grigoryev, E, Fritz, H, Bach, F, Schröder, S, Weyland, A, Gottschaldt, U, Menzel, M, Zachariae, O, Novak, R, Berden, J, Haake, H, Quintel, M, Kloesel, S, Kortgen, A, Stecher, S, Torti, P, Nestler, F, Nitsch, M, Olboeter, D, Muck, P, Findeisen, M, Bitzinger, D, Kraßler, J, Benad, M, Schott, M, Schumacher, U, Molnar, Z & Brunkhorst, FM 2022, 'Hemoadsorption in the critically ill-Final results of the International CytoSorb Registry', PLoS One, vol. 17, no. 10, pp. e0274315. https://doi.org/10.1371/journal.pone.0274315
@article{0b3e7e64af9144519df90fa5c586e3ae,
title = "Hemoadsorption in the critically ill-Final results of the International CytoSorb Registry",
abstract = "The aim of the current paper is to summarize the results of the International CytoSorb Registry. Data were collected on patients of the intensive care unit. The primary endpoint was actual in-hospital mortality compared to the mortality predicted by APACHE II score. The main secondary endpoints were SOFA scores, inflammatory biomarkers and overall evaluation of the general condition. 1434 patients were enrolled. Indications for hemoadsorption were sepsis/septic shock (N = 936); cardiac surgery perioperatively (N = 172); cardiac surgery postoperatively (N = 67) and {"}other{"} reasons (N = 259). APACHE-II-predicted mortality was 62.0±24.8%, whereas observed hospital mortality was 50.1%. Overall SOFA scores did not change but cardiovascular and pulmonary SOFA scores decreased by 0.4 [-0.5;-0.3] and -0.2 [-0.3;-0.2] points, respectively. Serum procalcitonin and C-reactive protein levels showed significant reduction: -15.4 [-19.6;-11.17] ng/mL; -17,52 [-70;44] mg/L, respectively. In the septic cohort PCT and IL-6 also showed significant reduction: -18.2 [-23.6;-12.8] ng/mL; -2.6 [-3.0;-2.2] pg/mL, respectively. Evaluation of the overall effect: minimal improvement (22%), much improvement (22%) and very much improvement (10%), no change observed (30%) and deterioration (4%). There was no significant difference in the primary outcome of mortality, but there were improvements in cardiovascular and pulmonary SOFA scores and a reduction in PCT, CRP and IL-6 levels. Trial registration: ClinicalTrials.gov Identifier: NCT02312024 (retrospectively registered).",
author = "Fatime Hawchar and Dana Tomescu and Karl Tr{\"a}ger and Dominik Joskowiak and Klaus Kogelmann and Jens Soukup and Singrun Friesecke and David Jacob and Jan Gummert and Andreas Faltlhauser and Filippo Aucella and {van Tellingen}, Martijn and Malbrain, {Manu L.N.G.} and Ralph Bogdanski and G{\"u}nter Weiss and Andreas Herbrich and Stefan Utzolino and Axel Nierhaus and Andreas Baumann and Andreas Hartjes and Dietrich Henzler and Evgeny Grigoryev and Harald Fritz and Friedhelm Bach and Stefan Schr{\"o}der and Andreas Weyland and Udo Gottschaldt and Matthias Menzel and Olivier Zachariae and Radovan Novak and Jernej Berden and Hendrik Haake and Michael Quintel and Stephan Kloesel and Andreas Kortgen and Stephanie Stecher and Patricia Torti and Frieder Nestler and Markus Nitsch and Detlef Olboeter and Philip Muck and Michael Findeisen and Diane Bitzinger and Jens Kra{\ss}ler and Martin Benad and Martin Schott and Ulrike Schumacher and Zsolt Molnar and Brunkhorst, {Frank Martin}",
year = "2022",
doi = "10.1371/journal.pone.0274315",
language = "English",
volume = "17",
pages = "e0274315",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",
}
TY - JOUR
T1 - Hemoadsorption in the critically ill-Final results of the International CytoSorb Registry
AU - Hawchar, Fatime
AU - Tomescu, Dana
AU - Träger, Karl
AU - Joskowiak, Dominik
AU - Kogelmann, Klaus
AU - Soukup, Jens
AU - Friesecke, Singrun
AU - Jacob, David
AU - Gummert, Jan
AU - Faltlhauser, Andreas
AU - Aucella, Filippo
AU - van Tellingen, Martijn
AU - Malbrain, Manu L.N.G.
AU - Bogdanski, Ralph
AU - Weiss, Günter
AU - Herbrich, Andreas
AU - Utzolino, Stefan
AU - Nierhaus, Axel
AU - Baumann, Andreas
AU - Hartjes, Andreas
AU - Henzler, Dietrich
AU - Grigoryev, Evgeny
AU - Fritz, Harald
AU - Bach, Friedhelm
AU - Schröder, Stefan
AU - Weyland, Andreas
AU - Gottschaldt, Udo
AU - Menzel, Matthias
AU - Zachariae, Olivier
AU - Novak, Radovan
AU - Berden, Jernej
AU - Haake, Hendrik
AU - Quintel, Michael
AU - Kloesel, Stephan
AU - Kortgen, Andreas
AU - Stecher, Stephanie
AU - Torti, Patricia
AU - Nestler, Frieder
AU - Nitsch, Markus
AU - Olboeter, Detlef
AU - Muck, Philip
AU - Findeisen, Michael
AU - Bitzinger, Diane
AU - Kraßler, Jens
AU - Benad, Martin
AU - Schott, Martin
AU - Schumacher, Ulrike
AU - Molnar, Zsolt
AU - Brunkhorst, Frank Martin
PY - 2022
Y1 - 2022
N2 - The aim of the current paper is to summarize the results of the International CytoSorb Registry. Data were collected on patients of the intensive care unit. The primary endpoint was actual in-hospital mortality compared to the mortality predicted by APACHE II score. The main secondary endpoints were SOFA scores, inflammatory biomarkers and overall evaluation of the general condition. 1434 patients were enrolled. Indications for hemoadsorption were sepsis/septic shock (N = 936); cardiac surgery perioperatively (N = 172); cardiac surgery postoperatively (N = 67) and "other" reasons (N = 259). APACHE-II-predicted mortality was 62.0±24.8%, whereas observed hospital mortality was 50.1%. Overall SOFA scores did not change but cardiovascular and pulmonary SOFA scores decreased by 0.4 [-0.5;-0.3] and -0.2 [-0.3;-0.2] points, respectively. Serum procalcitonin and C-reactive protein levels showed significant reduction: -15.4 [-19.6;-11.17] ng/mL; -17,52 [-70;44] mg/L, respectively. In the septic cohort PCT and IL-6 also showed significant reduction: -18.2 [-23.6;-12.8] ng/mL; -2.6 [-3.0;-2.2] pg/mL, respectively. Evaluation of the overall effect: minimal improvement (22%), much improvement (22%) and very much improvement (10%), no change observed (30%) and deterioration (4%). There was no significant difference in the primary outcome of mortality, but there were improvements in cardiovascular and pulmonary SOFA scores and a reduction in PCT, CRP and IL-6 levels. Trial registration: ClinicalTrials.gov Identifier: NCT02312024 (retrospectively registered).
AB - The aim of the current paper is to summarize the results of the International CytoSorb Registry. Data were collected on patients of the intensive care unit. The primary endpoint was actual in-hospital mortality compared to the mortality predicted by APACHE II score. The main secondary endpoints were SOFA scores, inflammatory biomarkers and overall evaluation of the general condition. 1434 patients were enrolled. Indications for hemoadsorption were sepsis/septic shock (N = 936); cardiac surgery perioperatively (N = 172); cardiac surgery postoperatively (N = 67) and "other" reasons (N = 259). APACHE-II-predicted mortality was 62.0±24.8%, whereas observed hospital mortality was 50.1%. Overall SOFA scores did not change but cardiovascular and pulmonary SOFA scores decreased by 0.4 [-0.5;-0.3] and -0.2 [-0.3;-0.2] points, respectively. Serum procalcitonin and C-reactive protein levels showed significant reduction: -15.4 [-19.6;-11.17] ng/mL; -17,52 [-70;44] mg/L, respectively. In the septic cohort PCT and IL-6 also showed significant reduction: -18.2 [-23.6;-12.8] ng/mL; -2.6 [-3.0;-2.2] pg/mL, respectively. Evaluation of the overall effect: minimal improvement (22%), much improvement (22%) and very much improvement (10%), no change observed (30%) and deterioration (4%). There was no significant difference in the primary outcome of mortality, but there were improvements in cardiovascular and pulmonary SOFA scores and a reduction in PCT, CRP and IL-6 levels. Trial registration: ClinicalTrials.gov Identifier: NCT02312024 (retrospectively registered).
UR - http://www.scopus.com/inward/record.url?scp=85140855911&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140855911&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0274315
DO - 10.1371/journal.pone.0274315
M3 - Article
C2 - 36282800
AN - SCOPUS:85140855911
SN - 1932-6203
VL - 17
SP - e0274315
JO - PLoS One
JF - PLoS One
IS - 10
ER -